Nelson Leong1, Pauline T Truong2, Keith Tankel3, Winkle Kwan4, Lorna Weir5, Ivo A Olivotto6. 1. Allan Blair Cancer Centre, Department of Radiation Oncology, University of Saskatchewan, Regina, Saskatchewan, Canada. Electronic address: nelson.leong@saskcancer.ca. 2. British Columbia Cancer Agency-Vancouver Island Centre, Division of Radiation Oncology, Department of Surgery, University of British Columbia, Victoria, British Columbia, Canada. 3. Cross Cancer Institute, Division of Radiation Oncology, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada. 4. British Columbia Cancer Agency-Fraser Valley Centre, Division of Radiation Oncology, Department of Surgery, University of British Columbia, Surrey, British Columbia, Canada. 5. British Columbia Cancer Agency-Vancouver Cancer Centre, Division of Radiation Oncology, Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada. 6. Tom Baker Cancer Centre, Division of Radiation Oncology, Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
Abstract
PURPOSE: To determine whether nodal radiation therapy (RT) for breast cancer using modest hypofractionation (HF) with 2.25 to 2.5 Gy per fraction (fx) was associated with increased patient-reported arm symptoms, compared with conventional fractionation (CF) ≤2 Gy/fx. METHODS AND MATERIALS: Two cancer registries were used to identify subjects who received computed tomography-planned nodal RT for pT1-3, pN0-2, M0 breast cancer, from 2007 to 2010 at 2 cancer institutions. After ethics approval, patients were mailed an explanatory letter and the Self-reported Arm Symptom Scale, a validated instrument with 8 questions about arm symptoms and 5 related to activities of daily living. Clinicopathologic characteristics and Self-reported Arm Symptom Scale scores were compared between HF/CF cohorts using nonparametric analysis, χ2 analysis, and multivariate ordinal regression. RESULTS: Of 1759 patients, 800 (45.5%) returned a completed survey. A total of 708 eligible cases formed the study cohort. Of these, 406 (57%) received HFRT (40 Gy/16 fx, 45 Gy/20 fx), and 302 (43%) received CFRT (45-50 Gy/25 fx, 50.4 Gy/28 fx). Median time interval after RT was 5.7 years. Forty-three percent and 75% of patients received breast-conserving surgery and chemotherapy, respectively. Twenty-two percent received breast boost RT, independent of fractionation. Median age at diagnosis was 59 years (HF) and 53 years (CF) (P<.001). The mean numbers of excised (n=12) and involved (n=3) nodes were similar between fractionation cohorts (P=.44), as were the mean sums of responses in arm symptoms (P=.17) and activities of daily living (P=.85). Patients receiving HF reported lower rates of shoulder stiffness (P=.04), trouble moving the arm (P=.02), and difficulty reaching overhead (P<.01) compared with the CF cohort. There was no difference in self-reported arm swelling or symptoms related to brachial plexopathy. CONCLUSIONS: Nodal RT with hypofractionation was not associated with increased patient-reported arm symptoms or functional deficits compared with CF. Subjects treated with CF reported more disability in certain aspects of arm/shoulder function. These data support shorter fractionation utilization when regional nodes are within the therapeutic target.
PURPOSE: To determine whether nodal radiation therapy (RT) for breast cancer using modest hypofractionation (HF) with 2.25 to 2.5 Gy per fraction (fx) was associated with increased patient-reported arm symptoms, compared with conventional fractionation (CF) ≤2 Gy/fx. METHODS AND MATERIALS: Two cancer registries were used to identify subjects who received computed tomography-planned nodal RT for pT1-3, pN0-2, M0 breast cancer, from 2007 to 2010 at 2 cancer institutions. After ethics approval, patients were mailed an explanatory letter and the Self-reported Arm Symptom Scale, a validated instrument with 8 questions about arm symptoms and 5 related to activities of daily living. Clinicopathologic characteristics and Self-reported Arm Symptom Scale scores were compared between HF/CF cohorts using nonparametric analysis, χ2 analysis, and multivariate ordinal regression. RESULTS: Of 1759 patients, 800 (45.5%) returned a completed survey. A total of 708 eligible cases formed the study cohort. Of these, 406 (57%) received HFRT (40 Gy/16 fx, 45 Gy/20 fx), and 302 (43%) received CFRT (45-50 Gy/25 fx, 50.4 Gy/28 fx). Median time interval after RT was 5.7 years. Forty-three percent and 75% of patients received breast-conserving surgery and chemotherapy, respectively. Twenty-two percent received breast boost RT, independent of fractionation. Median age at diagnosis was 59 years (HF) and 53 years (CF) (P<.001). The mean numbers of excised (n=12) and involved (n=3) nodes were similar between fractionation cohorts (P=.44), as were the mean sums of responses in arm symptoms (P=.17) and activities of daily living (P=.85). Patients receiving HF reported lower rates of shoulder stiffness (P=.04), trouble moving the arm (P=.02), and difficulty reaching overhead (P<.01) compared with the CF cohort. There was no difference in self-reported arm swelling or symptoms related to brachial plexopathy. CONCLUSIONS: Nodal RT with hypofractionation was not associated with increased patient-reported arm symptoms or functional deficits compared with CF. Subjects treated with CF reported more disability in certain aspects of arm/shoulder function. These data support shorter fractionation utilization when regional nodes are within the therapeutic target.
Authors: Michael Green; Samantha J Van Nest; Emilie Soisson; Kathryn Huber; Yixiang Liao; William McBride; Michael M Dominello; Jay Burmeister; Michael C Joiner Journal: J Appl Clin Med Phys Date: 2020-06 Impact factor: 2.102
Authors: Arantxa Eraso; Javier Sanz; Meritxell Mollà; Vicky Reyes; Agustí Pedro; Meritxell Arenas; Evelyn Martinez; Rosa Ballester; Maria José Cambra; Virginia García; Joan Lluis Prades; Josep M Borras; Manuel Algara Journal: Clin Transl Oncol Date: 2022-02-21 Impact factor: 3.340
Authors: C E Coles; C Aristei; J Bliss; L Boersma; A M Brunt; S Chatterjee; G Hanna; R Jagsi; O Kaidar Person; A Kirby; I Mjaaland; I Meattini; A M Luis; G N Marta; B Offersen; P Poortmans; S Rivera Journal: Clin Oncol (R Coll Radiol) Date: 2020-05 Impact factor: 4.126
Authors: Lior Z Braunstein; Erin F Gillespie; Linda Hong; Amy Xu; Samuel F Bakhoum; John Cuaron; Boris Mueller; Beryl McCormick; Oren Cahlon; Simon Powell; Atif J Khan Journal: Adv Radiat Oncol Date: 2020-04-01